#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	event	new	coref	5-1[26_0]

#Text=Tyrosine kinase inhibitors ( TKIs ) are widely used drugs as a targeted strategy for cancer treatment with the aim of prolonging progression-free survival .
2-1	16-24	Tyrosine	abstract|abstract[4]	new|new[4]	appos|coref	2-5[0_4]|3-2
2-2	25-31	kinase	abstract|abstract[4]	new|new[4]	coref	3-3
2-3	32-42	inhibitors	abstract[4]	new[4]	_	_
2-4	43-44	(	_	_	_	_
2-5	45-49	TKIs	abstract	giv	coref	4-7
2-6	50-51	)	_	_	_	_
2-7	52-55	are	_	_	_	_
2-8	56-62	widely	_	_	_	_
2-9	63-67	used	_	_	_	_
2-10	68-73	drugs	substance	new	coref	10-2[65_0]
2-11	74-76	as	_	_	_	_
2-12	77-78	a	_	_	_	_
2-13	79-87	targeted	_	_	_	_
2-14	88-96	strategy	_	_	_	_
2-15	97-100	for	_	_	_	_
2-16	101-107	cancer	abstract|event[8]	new|new[8]	coref	4-13[24_8]
2-17	108-117	treatment	event[8]	new[8]	_	_
2-18	118-122	with	event[8]	new[8]	_	_
2-19	123-126	the	event[8]|abstract[9]	new[8]|new[9]	_	_
2-20	127-130	aim	event[8]|abstract[9]	new[8]|new[9]	_	_
2-21	131-133	of	_	_	_	_
2-22	134-144	prolonging	_	_	_	_
2-23	145-161	progression-free	event[10]	new[10]	coref	5-30[35_10]
2-24	162-170	survival	event[10]	new[10]	_	_
2-25	171-172	.	_	_	_	_

#Text=Deregulated tyrosine kinase activity of the BCR-ABL oncoprotein is the biochemical hallmark of Philadelphia chromosome-positive ( Ph+ ) hematological malignancies .
3-1	173-184	Deregulated	abstract[13]	new[13]	coref	3-10[16_13]
3-2	185-193	tyrosine	abstract|abstract[13]	giv|new[13]	coref	10-28
3-3	194-200	kinase	abstract|abstract[13]	giv|new[13]	coref	10-12
3-4	201-209	activity	abstract[13]	new[13]	_	_
3-5	210-212	of	abstract[13]	new[13]	_	_
3-6	213-216	the	abstract[13]|substance[15]	new[13]|new[15]	_	_
3-7	217-224	BCR-ABL	abstract[13]|abstract|substance[15]	new[13]|new|new[15]	coref	4-6
3-8	225-236	oncoprotein	abstract[13]|substance[15]	new[13]|new[15]	_	_
3-9	237-239	is	_	_	_	_
3-10	240-243	the	abstract[16]	giv[16]	_	_
3-11	244-255	biochemical	abstract[16]	giv[16]	_	_
3-12	256-264	hallmark	abstract[16]	giv[16]	_	_
3-13	265-267	of	abstract[16]	giv[16]	_	_
3-14	268-280	Philadelphia	abstract[16]|person|event[19]	giv[16]|new|new[19]	coref	4-15[25_19]
3-15	281-300	chromosome-positive	abstract[16]|event[19]	giv[16]|new[19]	_	_
3-16	301-302	(	abstract[16]|event[19]	giv[16]|new[19]	_	_
3-17	303-306	Ph+	abstract[16]|abstract|event[19]	giv[16]|new|new[19]	coref	7-3
3-18	307-308	)	abstract[16]|event[19]	giv[16]|new[19]	_	_
3-19	309-322	hematological	abstract[16]|event[19]	giv[16]|new[19]	_	_
3-20	323-335	malignancies	abstract[16]|event[19]	giv[16]|new[19]	_	_
3-21	336-337	.	_	_	_	_

#Text=Currently , several generations of BCR-ABL TKIs are in clinical use for treatment of these malignancies .
4-1	338-347	Currently	_	_	_	_
4-2	348-349	,	_	_	_	_
4-3	350-357	several	abstract[20]	new[20]	_	_
4-4	358-369	generations	abstract[20]	new[20]	_	_
4-5	370-372	of	abstract[20]	new[20]	_	_
4-6	373-380	BCR-ABL	abstract[20]|abstract	new[20]|giv	coref	21-14
4-7	381-385	TKIs	abstract[20]|abstract	new[20]|giv	coref	5-3[27_0]
4-8	386-389	are	_	_	_	_
4-9	390-392	in	_	_	_	_
4-10	393-401	clinical	abstract[23]	new[23]	_	_
4-11	402-405	use	abstract[23]	new[23]	_	_
4-12	406-409	for	abstract[23]	new[23]	_	_
4-13	410-419	treatment	abstract[23]|event[24]	new[23]|giv[24]	coref	6-16[40_24]
4-14	420-422	of	abstract[23]|event[24]	new[23]|giv[24]	_	_
4-15	423-428	these	abstract[23]|event[24]|event[25]	new[23]|giv[24]|giv[25]	_	_
4-16	429-441	malignancies	abstract[23]|event[24]|event[25]	new[23]|giv[24]|giv[25]	_	_
4-17	442-443	.	_	_	_	_

#Text=Introduction of the second-generation TKIs , nilotinib and dasatinib as first-line treatment resulted in rapid and deep reduction of BCR/ABL1 allele transcripts , and this provided a possibility for long-term survival in CML .
5-1	444-456	Introduction	event[26]	giv[26]	_	_
5-2	457-459	of	event[26]	giv[26]	_	_
5-3	460-463	the	event[26]|abstract[27]	giv[26]|giv[27]	coref	8-13[50_27]
5-4	464-481	second-generation	event[26]|abstract[27]	giv[26]|giv[27]	_	_
5-5	482-486	TKIs	event[26]|abstract[27]	giv[26]|giv[27]	_	_
5-6	487-488	,	event[26]|abstract[27]	giv[26]|giv[27]	_	_
5-7	489-498	nilotinib	event[26]|abstract[27]|substance	giv[26]|giv[27]|new	coref	9-14
5-8	499-502	and	event[26]|abstract[27]	giv[26]|giv[27]	_	_
5-9	503-512	dasatinib	event[26]|abstract[27]|substance[29]	giv[26]|giv[27]|new[29]	coref	9-21[0_29]
5-10	513-515	as	event[26]|abstract[27]|substance[29]	giv[26]|giv[27]|new[29]	_	_
5-11	516-526	first-line	event[26]|abstract[27]|substance[29]	giv[26]|giv[27]|new[29]	_	_
5-12	527-536	treatment	event[26]|abstract[27]|substance[29]	giv[26]|giv[27]|new[29]	_	_
5-13	537-545	resulted	_	_	_	_
5-14	546-548	in	_	_	_	_
5-15	549-554	rapid	abstract[30]	new[30]	ana	5-25[0_30]
5-16	555-558	and	abstract[30]	new[30]	_	_
5-17	559-563	deep	abstract[30]	new[30]	_	_
5-18	564-573	reduction	abstract[30]	new[30]	_	_
5-19	574-576	of	abstract[30]	new[30]	_	_
5-20	577-585	BCR/ABL1	abstract[30]|object|object[32]	new[30]|new|new[32]	_	_
5-21	586-592	allele	abstract[30]|object[32]	new[30]|new[32]	_	_
5-22	593-604	transcripts	abstract[30]|object[32]	new[30]|new[32]	_	_
5-23	605-606	,	_	_	_	_
5-24	607-610	and	_	_	_	_
5-25	611-615	this	abstract	giv	_	_
5-26	616-624	provided	_	_	_	_
5-27	625-626	a	abstract[34]	new[34]	_	_
5-28	627-638	possibility	abstract[34]	new[34]	_	_
5-29	639-642	for	abstract[34]	new[34]	_	_
5-30	643-652	long-term	abstract[34]|event[35]	new[34]|giv[35]	_	_
5-31	653-661	survival	abstract[34]|event[35]	new[34]|giv[35]	_	_
5-32	662-664	in	abstract[34]|event[35]	new[34]|giv[35]	_	_
5-33	665-668	CML	abstract[34]|event[35]|abstract	new[34]|giv[35]|new	coref	6-4
5-34	669-670	.	_	_	_	_

#Text=In addition to CML , several other patient populations were identified that undoubtedly benefited from TKI treatment .
6-1	671-673	In	_	_	_	_
6-2	674-682	addition	_	_	_	_
6-3	683-685	to	_	_	_	_
6-4	686-689	CML	abstract	giv	coref	28-32
6-5	690-691	,	_	_	_	_
6-6	692-699	several	person[38]	new[38]	_	_
6-7	700-705	other	person[38]	new[38]	_	_
6-8	706-713	patient	person[38]	new[38]	_	_
6-9	714-725	populations	person[38]	new[38]	_	_
6-10	726-730	were	_	_	_	_
6-11	731-741	identified	_	_	_	_
6-12	742-746	that	_	_	_	_
6-13	747-758	undoubtedly	_	_	_	_
6-14	759-768	benefited	_	_	_	_
6-15	769-773	from	_	_	_	_
6-16	774-777	TKI	event|event[40]	new|giv[40]	coref	7-17
6-17	778-787	treatment	event[40]	giv[40]	_	_
6-18	788-789	.	_	_	_	_

#Text=Patients with Ph+ adult acute lymphoblastic leukemia ( ALL ) may also benefit from an alternate TKI therapy .
7-1	790-798	Patients	abstract[41]	new[41]	_	_
7-2	799-803	with	abstract[41]	new[41]	_	_
7-3	804-807	Ph+	abstract[41]|abstract|abstract[43]	new[41]|giv|new[43]	coref	8-8
7-4	808-813	adult	abstract[41]|abstract[43]	new[41]|new[43]	_	_
7-5	814-819	acute	abstract[41]|abstract[43]	new[41]|new[43]	_	_
7-6	820-833	lymphoblastic	abstract[41]|abstract[43]	new[41]|new[43]	_	_
7-7	834-842	leukemia	abstract[41]|abstract[43]	new[41]|new[43]	_	_
7-8	843-844	(	_	_	_	_
7-9	845-848	ALL	_	_	_	_
7-10	849-850	)	_	_	_	_
7-11	851-854	may	_	_	_	_
7-12	855-859	also	_	_	_	_
7-13	860-867	benefit	_	_	_	_
7-14	868-872	from	_	_	_	_
7-15	873-875	an	abstract[45]	new[45]	_	_
7-16	876-885	alternate	abstract[45]	new[45]	_	_
7-17	886-889	TKI	abstract|abstract[45]	giv|new[45]	_	_
7-18	890-897	therapy	abstract[45]	new[45]	_	_
7-19	898-899	.	_	_	_	_

#Text=In the treatment of pediatric patients with Ph+ ALL the addition of TKIs to conventional chemotherapy has improved outcomes of patients .
8-1	900-902	In	_	_	_	_
8-2	903-906	the	abstract[46]	new[46]	_	_
8-3	907-916	treatment	abstract[46]	new[46]	_	_
8-4	917-919	of	abstract[46]	new[46]	_	_
8-5	920-929	pediatric	abstract[46]|person[47]	new[46]|new[47]	coref	8-21[0_47]
8-6	930-938	patients	abstract[46]|person[47]	new[46]|new[47]	_	_
8-7	939-943	with	abstract[46]|person[47]	new[46]|new[47]	_	_
8-8	944-947	Ph+	abstract[46]|person[47]|abstract	new[46]|new[47]|giv	_	_
8-9	948-951	ALL	abstract[49]	new[49]	_	_
8-10	952-955	the	abstract[49]	new[49]	_	_
8-11	956-964	addition	abstract[49]	new[49]	_	_
8-12	965-967	of	abstract[49]	new[49]	_	_
8-13	968-972	TKIs	abstract[49]|abstract[50]	new[49]|giv[50]	coref	9-7[55_50]
8-14	973-975	to	abstract[49]|abstract[50]	new[49]|giv[50]	_	_
8-15	976-988	conventional	abstract[49]|abstract[50]|abstract[51]	new[49]|giv[50]|new[51]	ana	9-1[0_51]
8-16	989-1001	chemotherapy	abstract[49]|abstract[50]|abstract[51]	new[49]|giv[50]|new[51]	_	_
8-17	1002-1005	has	_	_	_	_
8-18	1006-1014	improved	_	_	_	_
8-19	1015-1023	outcomes	abstract[52]	new[52]	_	_
8-20	1024-1026	of	abstract[52]	new[52]	_	_
8-21	1027-1035	patients	abstract[52]|person	new[52]|giv	ana	10-18
8-22	1036-1037	.	_	_	_	_

#Text=It has long been known that second-generation TKIs may have side effects as nilotinib can potentiate a prothrombotic state while dasatinib is known to cause platelet dysfunction e.g. impaired collagen-induced platelet adhesion and aggregation .
9-1	1038-1040	It	abstract	giv	_	_
9-2	1041-1044	has	_	_	_	_
9-3	1045-1049	long	_	_	_	_
9-4	1050-1054	been	_	_	_	_
9-5	1055-1060	known	_	_	_	_
9-6	1061-1065	that	_	_	_	_
9-7	1066-1083	second-generation	abstract[55]	giv[55]	coref	20-1[0_55]
9-8	1084-1088	TKIs	abstract[55]	giv[55]	_	_
9-9	1089-1092	may	_	_	_	_
9-10	1093-1097	have	_	_	_	_
9-11	1098-1102	side	abstract[56]	new[56]	coref	21-9[149_56]
9-12	1103-1110	effects	abstract[56]	new[56]	_	_
9-13	1111-1113	as	_	_	_	_
9-14	1114-1123	nilotinib	substance	giv	coref	12-1
9-15	1124-1127	can	_	_	_	_
9-16	1128-1138	potentiate	_	_	_	_
9-17	1139-1140	a	abstract[58]	new[58]	_	_
9-18	1141-1154	prothrombotic	abstract[58]	new[58]	_	_
9-19	1155-1160	state	abstract[58]	new[58]	_	_
9-20	1161-1166	while	_	_	_	_
9-21	1167-1176	dasatinib	substance	giv	coref	11-1
9-22	1177-1179	is	_	_	_	_
9-23	1180-1185	known	_	_	_	_
9-24	1186-1188	to	_	_	_	_
9-25	1189-1194	cause	_	_	_	_
9-26	1195-1203	platelet	object|abstract[61]	new|new[61]	coref	9-31
9-27	1204-1215	dysfunction	abstract[61]	new[61]	_	_
9-28	1216-1220	e.g.	_	_	_	_
9-29	1221-1229	impaired	_	_	_	_
9-30	1230-1246	collagen-induced	abstract[63]	new[63]	_	_
9-31	1247-1255	platelet	object|abstract[63]	giv|new[63]	coref	13-14
9-32	1256-1264	adhesion	abstract[63]	new[63]	_	_
9-33	1265-1268	and	_	_	_	_
9-34	1269-1280	aggregation	event	new	coref	13-12[101_0]
9-35	1281-1282	.	_	_	_	_

#Text=Although both drugs bind to the ATP binding site of the kinase domain of the BCR/ABL protein they have different off target inhibitory effect on several other tyrosine kinases .
10-1	1283-1291	Although	_	_	_	_
10-2	1292-1296	both	substance[65]	giv[65]	_	_
10-3	1297-1302	drugs	substance[65]	giv[65]	_	_
10-4	1303-1307	bind	_	_	_	_
10-5	1308-1310	to	_	_	_	_
10-6	1311-1314	the	place[68]	new[68]	_	_
10-7	1315-1318	ATP	abstract|place[68]	new|new[68]	_	_
10-8	1319-1326	binding	object|place[68]	new|new[68]	coref	25-6[180_0]
10-9	1327-1331	site	place[68]	new[68]	_	_
10-10	1332-1334	of	place[68]	new[68]	_	_
10-11	1335-1338	the	place[68]|place[70]	new[68]|new[70]	_	_
10-12	1339-1345	kinase	place[68]|abstract|place[70]	new[68]|giv|new[70]	coref	22-23[161_0]
10-13	1346-1352	domain	place[68]|place[70]	new[68]|new[70]	_	_
10-14	1353-1355	of	place[68]|place[70]	new[68]|new[70]	_	_
10-15	1356-1359	the	place[68]|place[70]|object[72]	new[68]|new[70]|new[72]	_	_
10-16	1360-1367	BCR/ABL	place[68]|place[70]|object|object[72]	new[68]|new[70]|new|new[72]	_	_
10-17	1368-1375	protein	place[68]|place[70]|object[72]	new[68]|new[70]|new[72]	_	_
10-18	1376-1380	they	person	giv	coref	28-32[209_0]
10-19	1381-1385	have	_	_	_	_
10-20	1386-1395	different	abstract[75]	new[75]	coref	14-6[103_75]
10-21	1396-1399	off	abstract[75]	new[75]	_	_
10-22	1400-1406	target	abstract|abstract[75]	new|new[75]	_	_
10-23	1407-1417	inhibitory	abstract[75]	new[75]	_	_
10-24	1418-1424	effect	abstract[75]	new[75]	_	_
10-25	1425-1427	on	abstract[75]	new[75]	_	_
10-26	1428-1435	several	abstract[75]|abstract[77]	new[75]|new[77]	coref	12-14[91_77]
10-27	1436-1441	other	abstract[75]|abstract[77]	new[75]|new[77]	_	_
10-28	1442-1450	tyrosine	abstract[75]|abstract|abstract[77]	new[75]|giv|new[77]	coref	12-15
10-29	1451-1458	kinases	abstract[75]|abstract[77]	new[75]|new[77]	_	_
10-30	1459-1460	.	_	_	_	_

#Text=Dasatinib is a potent multikinase inhibitor , including c-KIT , EPHA2 , platelet-derived growth factor receptor-β , and SFKs .
11-1	1461-1470	Dasatinib	abstract	giv	coref	11-3[79_0]
11-2	1471-1473	is	_	_	_	_
11-3	1474-1475	a	abstract[79]	giv[79]	coref	13-9[0_79]
11-4	1476-1482	potent	abstract[79]	giv[79]	_	_
11-5	1483-1494	multikinase	abstract[79]	giv[79]	_	_
11-6	1495-1504	inhibitor	abstract[79]	giv[79]	_	_
11-7	1505-1506	,	abstract[79]	giv[79]	_	_
11-8	1507-1516	including	abstract[79]	giv[79]	_	_
11-9	1517-1522	c-KIT	abstract[79]|substance	giv[79]|new	coref	12-20
11-10	1523-1524	,	abstract[79]	giv[79]	_	_
11-11	1525-1530	EPHA2	abstract[79]|object	giv[79]|new	_	_
11-12	1531-1532	,	abstract[79]	giv[79]	_	_
11-13	1533-1549	platelet-derived	abstract[79]|abstract[82]|abstract[84]	giv[79]|new[82]|new[84]	_	_
11-14	1550-1556	growth	abstract[79]|abstract[82]|abstract[84]	giv[79]|new[82]|new[84]	_	_
11-15	1557-1563	factor	abstract[79]|abstract|abstract[84]	giv[79]|new|new[84]	_	_
11-16	1564-1574	receptor-β	abstract[79]|abstract[84]	giv[79]|new[84]	_	_
11-17	1575-1576	,	abstract[79]	giv[79]	_	_
11-18	1577-1580	and	abstract[79]	giv[79]	_	_
11-19	1581-1585	SFKs	abstract[79]|place	giv[79]|new	coref	12-32
11-20	1586-1587	.	_	_	_	_

#Text=Nilotinib is also a second generation TKI with a broad inhibitory spectrum of various tyrosine kinases ( PDGFR , c-KIT , ARG , EPHB4 ) , but it does not inhibit SFKs .
12-1	1588-1597	Nilotinib	abstract	giv	coref	12-4[87_0]
12-2	1598-1600	is	_	_	_	_
12-3	1601-1605	also	_	_	_	_
12-4	1606-1607	a	abstract[87]	giv[87]	appos	12-7[88_87]
12-5	1608-1614	second	abstract[87]	giv[87]	_	_
12-6	1615-1625	generation	abstract[87]	giv[87]	_	_
12-7	1626-1629	TKI	abstract[88]	giv[88]	coref	14-2[102_88]
12-8	1630-1634	with	abstract[88]	giv[88]	_	_
12-9	1635-1636	a	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
12-10	1637-1642	broad	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
12-11	1643-1653	inhibitory	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
12-12	1654-1662	spectrum	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
12-13	1663-1665	of	abstract[88]|abstract[89]	giv[88]|new[89]	_	_
12-14	1666-1673	various	abstract[88]|abstract[89]|abstract[91]	giv[88]|new[89]|giv[91]	appos	12-18[93_91]
12-15	1674-1682	tyrosine	abstract[88]|abstract[89]|abstract|abstract[91]	giv[88]|new[89]|giv|giv[91]	_	_
12-16	1683-1690	kinases	abstract[88]|abstract[89]|abstract[91]	giv[88]|new[89]|giv[91]	_	_
12-17	1691-1692	(	_	_	_	_
12-18	1693-1698	PDGFR	object|abstract[93]	new|giv[93]	coref	17-1[118_93]
12-19	1699-1700	,	abstract[93]	giv[93]	_	_
12-20	1701-1706	c-KIT	abstract[93]|abstract	giv[93]|giv	_	_
12-21	1707-1708	,	abstract[93]	giv[93]	_	_
12-22	1709-1712	ARG	abstract[93]	giv[93]	_	_
12-23	1713-1714	,	_	_	_	_
12-24	1715-1720	EPHB4	abstract	new	ana	12-28
12-25	1721-1722	)	_	_	_	_
12-26	1723-1724	,	_	_	_	_
12-27	1725-1728	but	_	_	_	_
12-28	1729-1731	it	abstract	giv	_	_
12-29	1732-1736	does	_	_	_	_
12-30	1737-1740	not	_	_	_	_
12-31	1741-1748	inhibit	_	_	_	_
12-32	1749-1753	SFKs	abstract	giv	coref	16-5
12-33	1754-1755	.	_	_	_	_

#Text=Previous in vitro and ex vivo studies with dasatinib have demonstrated a faulty platelet aggregation .
13-1	1756-1764	Previous	_	_	_	_
13-2	1765-1767	in	_	_	_	_
13-3	1768-1773	vitro	_	_	_	_
13-4	1774-1777	and	_	_	_	_
13-5	1778-1780	ex	_	_	_	_
13-6	1781-1785	vivo	event[98]	new[98]	_	_
13-7	1786-1793	studies	event[98]	new[98]	_	_
13-8	1794-1798	with	event[98]	new[98]	_	_
13-9	1799-1808	dasatinib	event[98]|substance	new[98]|giv	coref	27-6
13-10	1809-1813	have	_	_	_	_
13-11	1814-1826	demonstrated	_	_	_	_
13-12	1827-1828	a	event[101]	giv[101]	coref	14-9[105_101]
13-13	1829-1835	faulty	event[101]	giv[101]	_	_
13-14	1836-1844	platelet	object|event[101]	giv|giv[101]	coref	14-9
13-15	1845-1856	aggregation	event[101]	giv[101]	_	_
13-16	1857-1858	.	_	_	_	_

#Text=On the contrary nilotinib has no effect on platelet aggregation , at all .
14-1	1859-1861	On	_	_	_	_
14-2	1862-1865	the	substance[102]	giv[102]	coref	15-5[0_102]
14-3	1866-1874	contrary	substance[102]	giv[102]	_	_
14-4	1875-1884	nilotinib	substance[102]	giv[102]	_	_
14-5	1885-1888	has	_	_	_	_
14-6	1889-1891	no	abstract[103]	giv[103]	coref	20-3[145_103]
14-7	1892-1898	effect	abstract[103]	giv[103]	_	_
14-8	1899-1901	on	abstract[103]	giv[103]	_	_
14-9	1902-1910	platelet	abstract[103]|object|event[105]	giv[103]|giv|giv[105]	ana|coref	14-13[0_105]|16-11
14-10	1911-1922	aggregation	abstract[103]|event[105]	giv[103]|giv[105]	_	_
14-11	1923-1924	,	_	_	_	_
14-12	1925-1927	at	_	_	_	_
14-13	1928-1931	all	event	giv	coref	23-16[170_0]
14-14	1932-1933	.	_	_	_	_

#Text=Therefore , we used nilotinib as a negative control in our experiments .
15-1	1934-1943	Therefore	_	_	_	_
15-2	1944-1945	,	_	_	_	_
15-3	1946-1948	we	person	acc	ana	15-11
15-4	1949-1953	used	_	_	_	_
15-5	1954-1963	nilotinib	substance	giv	coref	22-31
15-6	1964-1966	as	_	_	_	_
15-7	1967-1968	a	_	_	_	_
15-8	1969-1977	negative	_	_	_	_
15-9	1978-1985	control	_	_	_	_
15-10	1986-1988	in	_	_	_	_
15-11	1989-1992	our	person|abstract[110]	giv|new[110]	ana	27-1
15-12	1993-2004	experiments	abstract[110]	new[110]	_	_
15-13	2005-2006	.	_	_	_	_

#Text=Sarcoma family kinases ( SFKs ) are critical regulators of platelet signaling and activation .
16-1	2007-2014	Sarcoma	abstract|person[112]	new|new[112]	_	_
16-2	2015-2021	family	person[112]	new[112]	_	_
16-3	2022-2029	kinases	_	_	_	_
16-4	2030-2031	(	_	_	_	_
16-5	2032-2036	SFKs	abstract	giv	coref	19-11
16-6	2037-2038	)	_	_	_	_
16-7	2039-2042	are	_	_	_	_
16-8	2043-2051	critical	substance[114]	new[114]	_	_
16-9	2052-2062	regulators	substance[114]	new[114]	_	_
16-10	2063-2065	of	substance[114]	new[114]	_	_
16-11	2066-2074	platelet	substance[114]|object|abstract[116]	new[114]|giv|new[116]	coref|coref	18-8|19-28[139_116]
16-12	2075-2084	signaling	substance[114]|abstract[116]	new[114]|new[116]	_	_
16-13	2085-2088	and	substance[114]	new[114]	_	_
16-14	2089-2099	activation	substance[114]|event	new[114]|new	coref	18-3
16-15	2100-2101	.	_	_	_	_

#Text=These kinases play a central role in mediating rapid response of platelets to vascular injury .
17-1	2102-2107	These	abstract[118]	giv[118]	coref	22-18[0_118]
17-2	2108-2115	kinases	abstract[118]	giv[118]	_	_
17-3	2116-2120	play	_	_	_	_
17-4	2121-2122	a	abstract[119]	new[119]	_	_
17-5	2123-2130	central	abstract[119]	new[119]	_	_
17-6	2131-2135	role	abstract[119]	new[119]	_	_
17-7	2136-2138	in	_	_	_	_
17-8	2139-2148	mediating	_	_	_	_
17-9	2149-2154	rapid	abstract[120]	new[120]	coref	28-17[203_120]
17-10	2155-2163	response	abstract[120]	new[120]	_	_
17-11	2164-2166	of	abstract[120]	new[120]	_	_
17-12	2167-2176	platelets	abstract[120]|object	new[120]|new	ana	18-1
17-13	2177-2179	to	_	_	_	_
17-14	2180-2188	vascular	event[122]	new[122]	coref	23-2[165_122]
17-15	2189-2195	injury	event[122]	new[122]	_	_
17-16	2196-2197	.	_	_	_	_

#Text=They transmit activation signals from several various platelet receptors .
18-1	2198-2202	They	object	giv	coref	19-42[142_0]
18-2	2203-2211	transmit	_	_	_	_
18-3	2212-2222	activation	abstract|abstract[125]	giv|new[125]	coref	19-22[134_0]
18-4	2223-2230	signals	abstract[125]	new[125]	_	_
18-5	2231-2235	from	_	_	_	_
18-6	2236-2243	several	object[127]	new[127]	_	_
18-7	2244-2251	various	object[127]	new[127]	_	_
18-8	2252-2260	platelet	object|object[127]	giv|new[127]	coref	23-17
18-9	2261-2270	receptors	object[127]	new[127]	_	_
18-10	2271-2272	.	_	_	_	_

#Text=There are numerous members of this group and among the SFKs Lyn , Fyn , and Src have been implicated in activation of the GPVI receptor and the integrin receptor signaling and are frequently studied proteins as they are present in both human and mouse platelets .
19-1	2273-2278	There	_	_	_	_
19-2	2279-2282	are	_	_	_	_
19-3	2283-2291	numerous	person[128]	new[128]	ana	19-38[0_128]
19-4	2292-2299	members	person[128]	new[128]	_	_
19-5	2300-2302	of	person[128]	new[128]	_	_
19-6	2303-2307	this	person[128]|abstract[129]	new[128]|new[129]	_	_
19-7	2308-2313	group	person[128]|abstract[129]	new[128]|new[129]	_	_
19-8	2314-2317	and	_	_	_	_
19-9	2318-2323	among	_	_	_	_
19-10	2324-2327	the	person[131]	new[131]	coref	22-11[0_131]
19-11	2328-2332	SFKs	place|person[131]	giv|new[131]	coref	22-5[153_0]
19-12	2333-2336	Lyn	person[131]	new[131]	_	_
19-13	2337-2338	,	_	_	_	_
19-14	2339-2342	Fyn	abstract	new	_	_
19-15	2343-2344	,	_	_	_	_
19-16	2345-2348	and	_	_	_	_
19-17	2349-2352	Src	abstract	new	coref	22-16
19-18	2353-2357	have	_	_	_	_
19-19	2358-2362	been	_	_	_	_
19-20	2363-2373	implicated	_	_	_	_
19-21	2374-2376	in	_	_	_	_
19-22	2377-2387	activation	event[134]	giv[134]	_	_
19-23	2388-2390	of	event[134]	giv[134]	_	_
19-24	2391-2394	the	event[134]|substance[136]	giv[134]|new[136]	coref	19-30[0_136]
19-25	2395-2399	GPVI	event[134]|abstract|substance[136]	giv[134]|new|new[136]	_	_
19-26	2400-2408	receptor	event[134]|substance[136]	giv[134]|new[136]	_	_
19-27	2409-2412	and	event[134]	giv[134]	_	_
19-28	2413-2416	the	event[134]|abstract[139]	giv[134]|giv[139]	_	_
19-29	2417-2425	integrin	event[134]|person|abstract[139]	giv[134]|new|giv[139]	_	_
19-30	2426-2434	receptor	event[134]|substance|abstract[139]	giv[134]|giv|giv[139]	_	_
19-31	2435-2444	signaling	event[134]|abstract[139]	giv[134]|giv[139]	_	_
19-32	2445-2448	and	_	_	_	_
19-33	2449-2452	are	_	_	_	_
19-34	2453-2463	frequently	_	_	_	_
19-35	2464-2471	studied	_	_	_	_
19-36	2472-2480	proteins	substance	new	_	_
19-37	2481-2483	as	_	_	_	_
19-38	2484-2488	they	person	giv	_	_
19-39	2489-2492	are	_	_	_	_
19-40	2493-2500	present	_	_	_	_
19-41	2501-2503	in	_	_	_	_
19-42	2504-2508	both	object[142]	giv[142]	coref	23-12[168_142]
19-43	2509-2514	human	object[142]	giv[142]	_	_
19-44	2515-2518	and	object[142]	giv[142]	_	_
19-45	2519-2524	mouse	object[142]	giv[142]	_	_
19-46	2525-2534	platelets	object[142]	giv[142]	_	_
19-47	2535-2536	.	_	_	_	_

#Text=TKIs have a different off-target multikinase inhibitory effect .
20-1	2537-2541	TKIs	event	giv	coref	21-15
20-2	2542-2546	have	_	_	_	_
20-3	2547-2548	a	abstract[145]	giv[145]	coref	29-14[215_145]
20-4	2549-2558	different	abstract[145]	giv[145]	_	_
20-5	2559-2569	off-target	abstract[145]	giv[145]	_	_
20-6	2570-2581	multikinase	abstract[145]	giv[145]	_	_
20-7	2582-2592	inhibitory	abstract|abstract[145]	new|giv[145]	_	_
20-8	2593-2599	effect	abstract[145]	giv[145]	_	_
20-9	2600-2601	.	_	_	_	_

#Text=Comprehensive drug-protein interaction profiles were described to predict the potential side effects of BCR-ABL TKIs .
21-1	2602-2615	Comprehensive	abstract[147]	new[147]	_	_
21-2	2616-2628	drug-protein	abstract[147]	new[147]	_	_
21-3	2629-2640	interaction	abstract|abstract[147]	new|new[147]	_	_
21-4	2641-2649	profiles	abstract[147]	new[147]	_	_
21-5	2650-2654	were	_	_	_	_
21-6	2655-2664	described	_	_	_	_
21-7	2665-2667	to	_	_	_	_
21-8	2668-2675	predict	_	_	_	_
21-9	2676-2679	the	abstract[149]	giv[149]	_	_
21-10	2680-2689	potential	abstract[149]	giv[149]	_	_
21-11	2690-2694	side	abstract|abstract[149]	new|giv[149]	_	_
21-12	2695-2702	effects	abstract[149]	giv[149]	_	_
21-13	2703-2705	of	abstract[149]	giv[149]	_	_
21-14	2706-2713	BCR-ABL	abstract[149]|abstract	giv[149]|giv	_	_
21-15	2714-2718	TKIs	abstract[149]|abstract	giv[149]|giv	ana	22-1
21-16	2719-2720	.	_	_	_	_

#Text=It was found that the most prominent dasatinib-targeted SFKs are Lyn , Fyn , and Src , kinases and their negative regulator C-terminal Src kinase ( Csk ) , but nilotinib does not bind to these kinases .
22-1	2721-2723	It	abstract	giv	_	_
22-2	2724-2727	was	_	_	_	_
22-3	2728-2733	found	_	_	_	_
22-4	2734-2738	that	_	_	_	_
22-5	2739-2742	the	place[153]	giv[153]	coref	22-11[155_153]
22-6	2743-2747	most	place[153]	giv[153]	_	_
22-7	2748-2757	prominent	place[153]	giv[153]	_	_
22-8	2758-2776	dasatinib-targeted	place[153]	giv[153]	_	_
22-9	2777-2781	SFKs	place[153]	giv[153]	_	_
22-10	2782-2785	are	_	_	_	_
22-11	2786-2789	Lyn	person|place[155]	giv|giv[155]	_	_
22-12	2790-2791	,	place[155]	giv[155]	_	_
22-13	2792-2795	Fyn	place[155]|person	giv[155]|new	_	_
22-14	2796-2797	,	place[155]	giv[155]	_	_
22-15	2798-2801	and	place[155]	giv[155]	_	_
22-16	2802-2805	Src	place[155]|abstract	giv[155]|giv	coref	22-24
22-17	2806-2807	,	place[155]	giv[155]	_	_
22-18	2808-2815	kinases	place[155]|abstract	giv[155]|giv	coref	22-36[164_0]
22-19	2816-2819	and	place[155]	giv[155]	_	_
22-20	2820-2825	their	place[155]|substance[159]	giv[155]|new[159]	_	_
22-21	2826-2834	negative	place[155]|substance[159]	giv[155]|new[159]	_	_
22-22	2835-2844	regulator	place[155]|substance[159]	giv[155]|new[159]	_	_
22-23	2845-2855	C-terminal	place[155]|abstract[161]	giv[155]|giv[161]	_	_
22-24	2856-2859	Src	place[155]|abstract|abstract[161]	giv[155]|giv|giv[161]	_	_
22-25	2860-2866	kinase	place[155]|abstract[161]	giv[155]|giv[161]	_	_
22-26	2867-2868	(	_	_	_	_
22-27	2869-2872	Csk	organization	new	_	_
22-28	2873-2874	)	_	_	_	_
22-29	2875-2876	,	_	_	_	_
22-30	2877-2880	but	_	_	_	_
22-31	2881-2890	nilotinib	substance	giv	ana	23-4
22-32	2891-2895	does	_	_	_	_
22-33	2896-2899	not	_	_	_	_
22-34	2900-2904	bind	_	_	_	_
22-35	2905-2907	to	_	_	_	_
22-36	2908-2913	these	abstract[164]	giv[164]	_	_
22-37	2914-2921	kinases	abstract[164]	giv[164]	_	_
22-38	2922-2923	.	_	_	_	_

#Text=During vascular injury it is primarily the subendothelial collagen that activates platelets and result in subsequent platelet aggregation .
23-1	2924-2930	During	_	_	_	_
23-2	2931-2939	vascular	event[165]	giv[165]	_	_
23-3	2940-2946	injury	event[165]	giv[165]	_	_
23-4	2947-2949	it	object	giv	coref	23-6[167_0]
23-5	2950-2952	is	_	_	_	_
23-6	2953-2962	primarily	object[167]	giv[167]	coref	25-15[184_167]
23-7	2963-2966	the	object[167]	giv[167]	_	_
23-8	2967-2981	subendothelial	object[167]	giv[167]	_	_
23-9	2982-2990	collagen	object[167]	giv[167]	_	_
23-10	2991-2995	that	_	_	_	_
23-11	2996-3005	activates	_	_	_	_
23-12	3006-3015	platelets	object[168]	giv[168]	coref	24-4[172_168]
23-13	3016-3019	and	object[168]	giv[168]	_	_
23-14	3020-3026	result	object[168]	giv[168]	_	_
23-15	3027-3029	in	object[168]	giv[168]	_	_
23-16	3030-3040	subsequent	object[168]|event[170]	giv[168]|giv[170]	_	_
23-17	3041-3049	platelet	object[168]|object|event[170]	giv[168]|giv|giv[170]	coref	27-10
23-18	3050-3061	aggregation	object[168]|event[170]	giv[168]|giv[170]	_	_
23-19	3062-3063	.	_	_	_	_

#Text=A population of the collagen-adhered platelets responds by surface exposure of the procoagulant phosphatidylserine ( PS ) .
24-1	3064-3065	A	abstract[171]	new[171]	_	_
24-2	3066-3076	population	abstract[171]	new[171]	_	_
24-3	3077-3079	of	abstract[171]	new[171]	_	_
24-4	3080-3083	the	abstract[171]|object[172]	new[171]|giv[172]	coref	26-4[0_172]
24-5	3084-3100	collagen-adhered	abstract[171]|object[172]	new[171]|giv[172]	_	_
24-6	3101-3110	platelets	abstract[171]|object[172]	new[171]|giv[172]	_	_
24-7	3111-3119	responds	_	_	_	_
24-8	3120-3122	by	_	_	_	_
24-9	3123-3130	surface	place|abstract[174]	new|new[174]	coref	25-1[178_0]
24-10	3131-3139	exposure	abstract[174]	new[174]	_	_
24-11	3140-3142	of	abstract[174]	new[174]	_	_
24-12	3143-3146	the	abstract[174]|substance[176]	new[174]|new[176]	_	_
24-13	3147-3159	procoagulant	abstract[174]|object|substance[176]	new[174]|new|new[176]	coref	27-11
24-14	3160-3178	phosphatidylserine	abstract[174]|substance[176]	new[174]|new[176]	_	_
24-15	3179-3180	(	_	_	_	_
24-16	3181-3183	PS	abstract	new	coref	25-4
24-17	3184-3185	)	_	_	_	_
24-18	3186-3187	.	_	_	_	_

#Text=This surface expressed PS facilitates the binding of coagulation factors and by this promotes thrombin generation .
25-1	3188-3192	This	place[178]	giv[178]	_	_
25-2	3193-3200	surface	place[178]	giv[178]	_	_
25-3	3201-3210	expressed	_	_	_	_
25-4	3211-3213	PS	abstract	giv	_	_
25-5	3214-3225	facilitates	_	_	_	_
25-6	3226-3229	the	object[180]	giv[180]	_	_
25-7	3230-3237	binding	object[180]	giv[180]	_	_
25-8	3238-3240	of	object[180]	giv[180]	_	_
25-9	3241-3252	coagulation	object[180]|abstract|abstract[182]	giv[180]|new|new[182]	coref	27-14[196_0]
25-10	3253-3260	factors	object[180]|abstract[182]	giv[180]|new[182]	_	_
25-11	3261-3264	and	_	_	_	_
25-12	3265-3267	by	_	_	_	_
25-13	3268-3272	this	_	_	_	_
25-14	3273-3281	promotes	_	_	_	_
25-15	3282-3290	thrombin	place|abstract[184]	new|giv[184]	coref	29-11[0_184]
25-16	3291-3301	generation	abstract[184]	giv[184]	_	_
25-17	3302-3303	.	_	_	_	_

#Text=In addition , platelets participate in fibrin formation and regulate the process of clot retraction .
26-1	3304-3306	In	_	_	_	_
26-2	3307-3315	addition	_	_	_	_
26-3	3316-3317	,	_	_	_	_
26-4	3318-3327	platelets	object	giv	coref	28-23[205_0]
26-5	3328-3339	participate	_	_	_	_
26-6	3340-3342	in	_	_	_	_
26-7	3343-3349	fibrin	person|event[187]	new|new[187]	_	_
26-8	3350-3359	formation	event[187]	new[187]	_	_
26-9	3360-3363	and	_	_	_	_
26-10	3364-3372	regulate	_	_	_	_
26-11	3373-3376	the	abstract[188]	new[188]	_	_
26-12	3377-3384	process	abstract[188]	new[188]	_	_
26-13	3385-3387	of	abstract[188]	new[188]	_	_
26-14	3388-3392	clot	abstract[188]|object|abstract[190]	new[188]|new|new[190]	coref|coref	29-24|29-24[220_190]
26-15	3393-3403	retraction	abstract[188]|abstract[190]	new[188]|new[190]	_	_
26-16	3404-3405	.	_	_	_	_

#Text=We intended to investigate whether dasatinib also affects the platelet procoagulant activity and thereby coagulation .
27-1	3406-3408	We	person	giv	ana	28-5
27-2	3409-3417	intended	_	_	_	_
27-3	3418-3420	to	_	_	_	_
27-4	3421-3432	investigate	_	_	_	_
27-5	3433-3440	whether	_	_	_	_
27-6	3441-3450	dasatinib	abstract	giv	coref	28-15
27-7	3451-3455	also	_	_	_	_
27-8	3456-3463	affects	_	_	_	_
27-9	3464-3467	the	abstract[195]	new[195]	coref	29-19[218_195]
27-10	3468-3476	platelet	object|abstract[195]	giv|new[195]	coref	28-17
27-11	3477-3489	procoagulant	person|abstract[195]	giv|new[195]	coref	28-18
27-12	3490-3498	activity	abstract[195]	new[195]	_	_
27-13	3499-3502	and	_	_	_	_
27-14	3503-3510	thereby	abstract[196]	giv[196]	_	_
27-15	3511-3522	coagulation	abstract[196]	giv[196]	_	_
27-16	3523-3524	.	_	_	_	_

#Text=For this reason , we examined the in vitro and ex vivo effects of dasatinib on platelet procoagulant response in dasatinib treated platelets of healthy volunteers and in samples derived from CML patients on dasatinib therapy .
28-1	3525-3528	For	_	_	_	_
28-2	3529-3533	this	abstract[197]	new[197]	_	_
28-3	3534-3540	reason	abstract[197]	new[197]	_	_
28-4	3541-3542	,	_	_	_	_
28-5	3543-3545	we	person	giv	ana	29-1
28-6	3546-3554	examined	_	_	_	_
28-7	3555-3558	the	_	_	_	_
28-8	3559-3561	in	_	_	_	_
28-9	3562-3567	vitro	_	_	_	_
28-10	3568-3571	and	_	_	_	_
28-11	3572-3574	ex	_	_	_	_
28-12	3575-3579	vivo	abstract[199]	new[199]	_	_
28-13	3580-3587	effects	abstract[199]	new[199]	_	_
28-14	3588-3590	of	abstract[199]	new[199]	_	_
28-15	3591-3600	dasatinib	abstract[199]|abstract	new[199]|giv	coref	28-21
28-16	3601-3603	on	_	_	_	_
28-17	3604-3612	platelet	object|abstract[203]	giv|giv[203]	coref	29-19
28-18	3613-3625	procoagulant	person|abstract[203]	giv|giv[203]	coref	29-20
28-19	3626-3634	response	abstract[203]	giv[203]	_	_
28-20	3635-3637	in	abstract[203]	giv[203]	_	_
28-21	3638-3647	dasatinib	abstract[203]|person	giv[203]|giv	coref	28-35
28-22	3648-3655	treated	_	_	_	_
28-23	3656-3665	platelets	object[205]	giv[205]	coref	29-34[222_205]
28-24	3666-3668	of	object[205]	giv[205]	_	_
28-25	3669-3676	healthy	object[205]|person[206]	giv[205]|new[206]	_	_
28-26	3677-3687	volunteers	object[205]|person[206]	giv[205]|new[206]	_	_
28-27	3688-3691	and	_	_	_	_
28-28	3692-3694	in	_	_	_	_
28-29	3695-3702	samples	object	new	_	_
28-30	3703-3710	derived	_	_	_	_
28-31	3711-3715	from	_	_	_	_
28-32	3716-3719	CML	abstract|person[209]	giv|giv[209]	_	_
28-33	3720-3728	patients	person[209]	giv[209]	_	_
28-34	3729-3731	on	person[209]	giv[209]	_	_
28-35	3732-3741	dasatinib	person[209]|abstract|abstract[211]	giv[209]|giv|new[211]	_	_
28-36	3742-3749	therapy	person[209]|abstract[211]	giv[209]|new[211]	_	_
28-37	3750-3751	.	_	_	_	_

#Text=We found that at therapeutic concentration dasatainib , but not nilotinib , has a strong inhibitory effect on platelet procoagulant activity and on clot retraction both in non activated as well as in convulxin activated platelets .
29-1	3752-3754	We	person	giv	_	_
29-2	3755-3760	found	_	_	_	_
29-3	3761-3765	that	_	_	_	_
29-4	3766-3768	at	_	_	_	_
29-5	3769-3780	therapeutic	abstract[213]	new[213]	_	_
29-6	3781-3794	concentration	abstract[213]	new[213]	_	_
29-7	3795-3805	dasatainib	abstract[213]	new[213]	_	_
29-8	3806-3807	,	_	_	_	_
29-9	3808-3811	but	_	_	_	_
29-10	3812-3815	not	_	_	_	_
29-11	3816-3825	nilotinib	substance	giv	_	_
29-12	3826-3827	,	_	_	_	_
29-13	3828-3831	has	_	_	_	_
29-14	3832-3833	a	abstract[215]	giv[215]	_	_
29-15	3834-3840	strong	abstract[215]	giv[215]	_	_
29-16	3841-3851	inhibitory	abstract[215]	giv[215]	_	_
29-17	3852-3858	effect	abstract[215]	giv[215]	_	_
29-18	3859-3861	on	abstract[215]	giv[215]	_	_
29-19	3862-3870	platelet	abstract[215]|object|abstract[218]	giv[215]|giv|giv[218]	_	_
29-20	3871-3883	procoagulant	abstract[215]|person|abstract[218]	giv[215]|giv|giv[218]	_	_
29-21	3884-3892	activity	abstract[215]|abstract[218]	giv[215]|giv[218]	_	_
29-22	3893-3896	and	_	_	_	_
29-23	3897-3899	on	_	_	_	_
29-24	3900-3904	clot	object|abstract[220]	giv|giv[220]	_	_
29-25	3905-3915	retraction	abstract[220]	giv[220]	_	_
29-26	3916-3920	both	abstract[220]	giv[220]	_	_
29-27	3921-3923	in	_	_	_	_
29-28	3924-3927	non	_	_	_	_
29-29	3928-3937	activated	_	_	_	_
29-30	3938-3940	as	_	_	_	_
29-31	3941-3945	well	_	_	_	_
29-32	3946-3948	as	_	_	_	_
29-33	3949-3951	in	_	_	_	_
29-34	3952-3961	convulxin	person|object[222]	new|giv[222]	_	_
29-35	3962-3971	activated	object[222]	giv[222]	_	_
29-36	3972-3981	platelets	object[222]	giv[222]	_	_
29-37	3982-3983	.	_	_	_	_
